EPS for Aptevo Therapeutics Inc. (APVO) Expected At $-0.59

October 11, 2018 - By Hazel Jackson

Analysts expect Aptevo Therapeutics Inc. (NASDAQ:APVO) to report $-0.59 EPS on November, 8.They anticipate $0.73 EPS change or 521.43 % from last quarter’s $0.14 EPS. After having $-0.58 EPS previously, Aptevo Therapeutics Inc.’s analysts see 1.72 % EPS growth. The stock increased 0.12% or $0.005 during the last trading session, reaching $4.335. About 35,661 shares traded. Aptevo Therapeutics Inc. (NASDAQ:APVO) has risen 188.14% since October 11, 2017 and is uptrending. It has outperformed by 172.52% the S&P500.

Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. The company has market cap of $98.27 million. The Company’s marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. It has a 86.7 P/E ratio. The company's marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals.

Another recent and important Aptevo Therapeutics Inc. (NASDAQ:APVO) news was published by Nasdaq.com which published an article titled: “Market Trends Toward New Normal in Aptevo Therapeutics, Bottomline Technologies, Allete, Air Lease, The Goodyear …” on October 10, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>